Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 12/20 | 0.51 |
| ▸ | THRA | P10827 | 5/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641063 | 0.85 | THRB (0.58) | THRBTHRA | |
| SCHEMBL6664958 | 0.84 | THRB (0.55) | THRBTHRA | |
| SCHEMBL7061433 | 0.84 | THRB (0.55) | THRBTHRA | |
| SCHEMBL7040382 | 0.84 | THRB (0.53) | THRBTHRAPGRBRD4BRD2 | |
| SCHEMBL4961712 | 0.83 | THRB (0.73) | THRBTHRA | |
| SCHEMBL6660463 | 0.83 | THRB (0.55) | THRBTHRA | |
| SCHEMBL6657910 | 0.81 | THRB (0.58) | THRBTHRABRD4BRD2BRD3 | |
| SCHEMBL6660665 | 0.81 | THRB (0.61) | THRBTHRA | |
| SCHEMBL6655890 | 0.81 | THRB (0.52) | THRBTHRA | |
| SCHEMBL6659652 | 0.81 | THRB (0.57) | THRBTHRABRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | ASPNES GARY E (US) | 2003-02-27 | — | — | US | disclosed |
| US-6441015-B2 | OBESITY, ANTIDIABETIC AGENTS, CARDIOVASCULAR DISORDERS | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | THRA, TSHR, THRB | THRB 3/4885THRA 1/4885PGR 623/4885 |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885PGR 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.